Achieve Life Sciences, Inc. (ACHV) Research

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Market snapshot

Symbol
ACHV
Price
$4.85
Day change
-9.51%
Market cap
$497.9M
P/E ratio
-4.98x
52-week range
2-6.16
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$13.00

Peer companies

  • Allogene Therapeutics, Inc. (ALLO)
  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Atea Pharmaceuticals, Inc. (AVIR)
  • Capricor Therapeutics, Inc. (CAPR)
  • Humacyte, Inc. (HUMA)
  • Immuneering Corporation (IMRX)
  • Sagimet Biosciences Inc. (SGMT)
  • Entrada Therapeutics, Inc. (TRDA)

Recent insider activity

  • Waldman Reid Alexander — A-Award (47250 shares) on 2026-05-29
  • Farrow Jeffrey S — A-Award (47250 shares) on 2026-05-29
  • Waldman Reid Alexander — trade (0 shares) on 2026-05-29
  • Farrow Jeffrey S — trade (0 shares) on 2026-05-29
  • Martin Christopher Nathan — A-Award (47250 shares) on 2026-05-11

Open Achieve Life Sciences, Inc. (ACHV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.